Zydus Lifesciences rose 1.43% to Rs 435.65 after the drug maker said that it has received a final approval from the United States Food and Drug Administration (USFDA) to market Acetaminophen Injection.
Acetaminophen injection is indicated to relieve mild to moderate pain and to reduce fever. It is also used in combination with opioid (narcotic) medications to relieve moderate to severe pain.
The pharmaceutical company said that the drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.
According to IQVIA MAT August 2022 data, Acetaminophen injection had annual sales of $72 million in the United States.
The group now has 330 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04, the drug maker stated.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
